Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin85.9%+3.7pp85.4%+3.6pp84.6%+3.2pp82.2%-1.5pp82.2%-0.7pp
Operating margin11.4%+22.3pp8.5%+25.9pp3.1%+27.2pp-4.7%+15.8pp-10.9%+15.4pp
Net margin3.8%+24.1pp0.2%+27.2pp-5.9%+27.8pp-13%+19.8pp-20.3%+17.3pp
Returns
Return on invested capital21.4%+34.4pp15%+36.8pp4.7%+29.1pp-6.2%+13.1pp-13%+11.0pp
Efficiency
Asset turnover0.9×+0.2×0.8×+0.2×0.8×+0.2×0.7×+0.2×0.7×+0.2×
Liquidity
Current ratio2.1×+0.4×2.2×+0.5×1.9×+0.1×1.9×-0.3×1.7×-0.7×
Leverage
Debt-to-equity19.9×18.9×
Net debt / EBITDA3.9×5.6×17.6×
Per Share
Book value per share$0.07+132%$0.08+139%-$0.00+97.5%-$0.12+6.8%-$0.23-253%
Valuation
Market capitalization$1B+18.3%$1.3B+158%$1.31B+211%$746.32M+136%$845.13M+178%
Price / earnings83.3×2,351.1×
Price / sales3.2×-0.6×4.5×+2.0×4.9×+2.7×+1.3×3.8×+2.0×
Price / book76.9×95.1×
EV / EBITDA30.8×55.3×157.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Xeris Biopharma Holdings, Inc.'s profit margins?
Xeris Biopharma Holdings, Inc. (XERS) runs a 85.9% gross margin and a 11.4% operating margin, with a 3.8% net margin.
Where do Xeris Biopharma Holdings, Inc.'s ratios come from?
Every ratio is computed from Xeris Biopharma Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.